| BIOCELLGRAFT-INC |
BIOCELLGRAFT-INC |
92%
|
In December 2025, we entered into an amended Sublicense and Marketing Agreement with BioCellgraft, Inc., to develop and commercialize certain of our advanced biomaterial products under private label … |
| DEFEYE-INC |
DEFEYE-INC |
92%
|
In October 2025, we entered into a collaboration and license agreement with Defeye, Inc. to develop, manufacture, and commercialize certain of our advanced biomaterial products for ophthalmic applica… |
| NEXGEL-INC |
NEXGEL-INC |
92%
|
the Amendment provides that: (i) the aggregate consideration payable to the Company under the Agreement is $13.3 million, consisting of an upfront cash payment of $8.3 million on the transaction comm… |
| ALLO |
Allogene Therapeutics, Inc. |
72%
|
. Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| ALLO |
Allogene Therapeutics, Inc. |
72%
|
Reciprocal relationship from ALLO graph: Reciprocal relationship from CELU graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from CELU graph: Reciprocal relationship from ALLO g… |
| ATRA |
Atara Biotherapeutics, Inc. |
72%
|
. Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| ATRA |
Atara Biotherapeutics, Inc. |
72%
|
Reciprocal relationship from ATRA graph: Reciprocal relationship from CELU graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived alloge… |
| CRSP |
CRISPR Therapeutics AG |
72%
|
Reciprocal relationship from CRSP graph: Reciprocal relationship from CELU graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived alloge… |
| CRSP |
CRISPR Therapeutics AG |
72%
|
. Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| DTIL |
Precision BioSciences, Inc. |
72%
|
Reciprocal relationship from DTIL graph: Reciprocal relationship from CELU graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived alloge… |
| DTIL |
Precision BioSciences, Inc. |
72%
|
. Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| IPSC |
Century Therapeutics, Inc. |
72%
|
Reciprocal relationship from IPSC graph: Reciprocal relationship from CELU graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived alloge… |
| IPSC |
Century Therapeutics, Inc. |
72%
|
. Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| NTLA |
Intellia Therapeutics, Inc. |
72%
|
. Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| NTLA |
Intellia Therapeutics, Inc. |
72%
|
Reciprocal relationship from NTLA graph: Reciprocal relationship from CELU graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from CELU graph: Reciprocal relationship from NTLA g… |
| ORGO |
Organogenesis Holdings Inc. |
72%
|
. Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| ORGO |
Organogenesis Holdings Inc. |
72%
|
Reciprocal relationship from ORGO graph: Reciprocal relationship from CELU graph: Reciprocal relationship from ORGO graph: Reciprocal relationship from CELU graph: Reciprocal relationship from ORGO g… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
. Stock-Based Compensation Expense The Company recorded stock-based compensation expense in the following expense categories of its consolidated statement of operations and comprehensive loss: Schedu… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from REGN graph: Reciprocal relationship from CELU graph: . Stock-Based Compensation Expense The Company recorded stock-based compensation expense in the following expense cat… |
| SGMO |
Sangamo Therapeutics, Inc. |
72%
|
Reciprocal relationship from SGMO graph: Reciprocal relationship from CELU graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived alloge… |
| SGMO |
Sangamo Therapeutics, Inc. |
72%
|
. Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p… |
| CELENIV-PTE-LTD |
CELENIV-PTE-LTD |
62%
|
fe. The Company’s Chairman and Chief Executive Officer, Dr. Robert Hariri, M.D, Ph.D., and director, Peter Diamandis, M.D., are founding partners of Fountain Life. 127 Investment in Defeye, Inc. On A… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
tic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there ha… |
| DISTRIBUTION-AGREEMENTS-SEQUENCE-LIFESCIENCE-INC |
DISTRIBUTION-AGREEMENTS-SEQUENCE-LIFESCIENCE-INC |
62%
|
. Stock-Based Compensation Expense The Company recorded stock-based compensation expense in the following expense categories of its consolidated statement of operations and comprehensive loss: Schedu… |
| FOUNTAIN-LIFE-MANAGEMENT-LLC |
FOUNTAIN-LIFE-MANAGEMENT-LLC |
62%
|
. As of December 31, 2025 the Company had not made any payments to Celeniv for the License Agreement. Pursuant to the License Agreement, the Company has the option (the “Option”) to purchase from Cel… |
| GENTING-INNOVATION-PTE-LTD |
GENTING-INNOVATION-PTE-LTD |
62%
|
. In addition, the Amended RWI Loan provided for the issuance of warrants to acquire up to an aggregate 300,000 shares of the Company’s Class A common stock (“RWI Warrant”), at a purchase price of $ … |
| HUMAN-CAPITAL-RESOURCES |
HUMAN-CAPITAL-RESOURCES |
62%
|
ral government was not required to pay more than $12 billion in Affordable Care Act risk corridor payments to third-party payors who argued the payments were owed to them. In April 2020, the United S… |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
thousands) Year Ended December 31, Percent 2025 2024 Change Change Revenues: Product sales, net $ 13,175 $ 35,336 $ (22,161 ) (62.7 )% Services 5,432 5,140 292 5.7 % License, royalty and other 7,943 … |
| SEQUENCE-LIFESCIENCE-INC |
SEQUENCE-LIFESCIENCE-INC |
62%
|
fe. The Company’s Chairman and Chief Executive Officer, Dr. Robert Hariri, M.D, Ph.D., and director, Peter Diamandis, M.D., are founding partners of Fountain Life. 127 Investment in Defeye, Inc. On A… |
| SOR |
Source Capital |
62%
|
Reciprocal relationship from SOR graph: Reciprocal relationship from CELU graph: Reciprocal relationship from SOR graph: Reciprocal relationship from CELU graph: ults, revenue or specific net income … |
